Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q2 FY20 results · Jul–Sep 2019
Astec LifeSciences reported revenue from operations of ₹140.21 crore (up 24.4% from Q2 FY19) and net profit of ₹5.29 crore (down 54.3% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 140.21 | 112.72 | +24.4% | 76.99 | +82.1% |
| Other income | 1.82 | 1.85 | −1.7% | 0.94 | +94.0% |
| Total income | 142.04 | 114.57 | +24.0% | 77.93 | +82.3% |
| Profit before tax | 7.83 | 17.91 | −56.3% | (1.72) | Turned profit |
| Net profit for the period | 5.29 | 11.57 | −54.3% | (1.11) | Turned profit |
| EPS, basic (₹) | 2.70 | 5.92 | −54.4% | (0.57) | Turned profit |
| Net margin (%) | 3.8 | 10.3 | -1.4 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 140.21 | 112.72 | +24.4% | 76.99 | +82.1% |
| Other income | 1.82 | 1.85 | −1.7% | 0.94 | +94.0% |
| Total income | 142.04 | 114.57 | +24.0% | 77.93 | +82.3% |
| Profit before tax | 7.81 | 17.90 | −56.4% | (1.74) | Turned profit |
| Net profit for the period | 5.27 | 11.57 | −54.4% | (1.12) | Turned profit |
| EPS, basic (₹) | 2.70 | 5.92 | −54.4% | (0.57) | Turned profit |
| Net margin (%) | 3.8 | 10.3 | -1.5 |
Consolidated
- Filed with BSE
- 30 Oct 2019, 16:33 IST
- Board meeting
- 25 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Oct 2019, 16:33 IST
- Board meeting
- 25 Oct 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE